MDXHNasdaqServices-Medical Laboratories
MDxHealth SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 3, 2026
$0.18−0.02 (-11.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
64.5%+21.0 pts over 5 years
Operating margin
-13.4%+133.6 pts over 5 years
Net margin
-31.1%+124.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.8% | +42.8% | +42.3% | – | |
| Gross profit | +26.3% | +53.6% | +54.0% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | -22.0% | |
| Current ratio | – | 1.77 | 1.08 | |
| Interest coverage | -83.7× | -17.6× | -0.6× | |
| Inventory turnover | – | – | 7.2× | |
| Capex to revenue | 0.6% | 2.9% | 1.1% | |
| Diluted shares | 0M | 8M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
MDxHealth generated $98.88M from operations and spent $8.78M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$98.88M
Used
$8.78M
Capital expenditure$8.78M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$33.52M
- Cash generatingOperating cash flow above zero-$2.19M
- Return on assets improvedROA up on the prior year-29.5% → -21.3%
- Earnings backed by cashOperating cash flow above net income-$2.19M vs -$33.52M
- Less leverageLong-term debt to assets fell32.4% → 51.5%
- Better liquidityCurrent ratio rose1.57 → 1.08
- No dilutionShare count did not rise33M → 50M
- Gross margin improvedGross margin up on the prior year61.23% → 64.55%
- More efficientAsset turnover rose0.70 → 0.69